Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Amolyt Pharma S.A.S.
Headquarters: Lyon, France
Website: N/A
Year Founded: 2014
Status: Acquired
BioCentury | Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Mar 19, 2024
Deals
AZ deepens radiopharma commitment via $2B Fusion takeout
Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Mar 19, 2024
Deals
Deals Report: AZ buys Amolyt for Phase III asset, Novartis takes out IFM Due
Plus: Merck gains access to Pearl Bio’s synthetic biology platform for up to $1B, Hansoh partners with Biotheus on bispecific ADCs, and more
BioCentury | Mar 14, 2024
Deals
AstraZeneca’s Amolyt takeout among largest ever for a French biotech
Deal for $800M up front adds hypoparathyroidism asset, now in Phase III, to AZ’s Alexion portfolio; shareholders could receive $250M milestone
BioCentury | Nov 14, 2023
Finance
Nov. 13 Quick Takes: Legend finds next CAR partner in Novartis
Plus: EQT, Forbion lead €129M A round for VectorY and updates from ViaNautis Bio, Cartesian, Aclaris, Anthos, Basilea, and Blueberry
BioCentury | Jan 7, 2023
Deals
Jan. 6 Quick Takes: Pfizer ‘externalizing’ some cancer, rare disease programs
Plus: Column Group leads Synthekine’s $100M series C, and updates from Amolyt, Perceive, bluebird bio, BioNTech and more
BioCentury | Jun 30, 2022
Management Tracks
FDA names Bumpus chief scientist, Marston CMO
Plus Beyer becomes CEO at Kures, and updates from NGM, Apexigen, Achilles and more
BioCentury | Mar 7, 2022
Finance
Aiming to be ‘European anchor’ in expansion rounds, Kurma raises €160M toward growth fund
Seeking to maintain bigger stakes in later rounds, Kurma raises growth fund amid turbulent public markets
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
Items per page:
1 - 10 of 10